Albert Quan, MD
Pediatric Nephrology · Dallas, TXNPI 1689615114
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,115 of the $5,547 with a category attached, or 92.2%. Azurity Pharmaceuticals, Inc. accounts for 92.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $5,183 and has fallen 98.1% since, to $100 in 2025.
Across 21 payments — averaging $264.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Azurity Pharmaceuticals, Inc.$5K
- Travere Therapeutics, Inc.$104
- AstraZeneca$68
- Novartis$61
- One Lambda, Inc.$49
- Novo Nordisk$46
- plus $105 from 4 others
What the payments were for
- Consulting fees$5,11592%
- Food & beverage$3927%
- Education$401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Azurity Pharmaceuticals, Inc. | 5 | $5,115 |
| Travere Therapeutics, Inc. | 2 | $104 |
| AstraZeneca(2 entities) | 3 | $68 |
| Novartis | 3 | $61 |
| One Lambda, Inc. | 1 | $49 |
| Novo Nordisk | 2 | $46 |
| Aurinia Pharma U.S., Inc. | 2 | $39 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Merck | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,547 in reported general payments places this provider in the 85th percentile of 61 pediatric nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrografTacrolimus | 18 | $20,472 |
| Mycophenolate Mofetil | 11 | $7,650 |
| Prednisone | 17 | $423 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 40 | $199 |
| Amlodipine Besylate | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Dallas
- Raymond QuigleyDallas$7K
- Mouin SeikalyDallas$4K
- Elizabeth BrownDallas$390
- Smitha VidiDallas$53
- Amanda ClarkDallas$29
- Amy BeckerCorpus Christi$77K
- Mini MichaelHouston$25K
- Rita SwinfordHouston$25K
- Ewa ElenbergHouston$16K
- Robert GillespieFort Worth$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.